XON - Intrexon Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.04
-0.79 (-8.95%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close8.83
Open8.75
Bid0.00 x 1000
Ask0.00 x 21500
Day's Range7.91 - 8.77
52 Week Range6.21 - 20.16
Volume2,337,568
Avg. Volume1,694,419
Market Cap1.285B
Beta (3Y Monthly)1.84
PE Ratio (TTM)N/A
EPS (TTM)-1.55
Earnings DateFeb 27, 2019 - Mar 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.50
Trade prices are not sourced from all markets
  • Oil recovers after dropping below $50
    Yahoo Finance Video2 months ago

    Oil recovers after dropping below $50

    Oil made a slight recovery from Thursday morning's lows. Yahoo Finance's Julie Hyman, Adam Shapiro, and Dan Roberts discuss with Benchmark Investments' CEO Kevin Kelly.

  • Markit18 hours ago

    See what the IHS Markit Score report has to say about Intrexon Corp.

    # Intrexon Corp ### NASDAQ/NGS:XON View full report here! ## Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is high ## Bearish sentiment Short interest | Negative Short interest is high for XON with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting XON. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $1.30 billion over the last one-month into ETFs that hold XON are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Can This Stock Go From Potential Zika Virus Savior to Marijuana Kingpin?
    Motley Fool2 days ago

    Can This Stock Go From Potential Zika Virus Savior to Marijuana Kingpin?

    There's a new cannabis player that demands your attention.

  • Intrexon Signs Licensing Agreement with Next Green Wave
    Zacks6 days ago

    Intrexon Signs Licensing Agreement with Next Green Wave

    Intrexon (XON) partners with Next Green Wave Holdings to utilize Intrexon's Botticelli next-generation plant propagation platform.

  • RETRANSMISSION: Next Green Wave Signs Licensing Agreement with Global Biotech Leader Intrexon
    Newsfile8 days ago

    RETRANSMISSION: Next Green Wave Signs Licensing Agreement with Global Biotech Leader Intrexon

    Companies to apply Intrexon's proprietary Botticelli(TM) platform toward rapid and sustainable cannabis plantlet production Coalinga, California and Davis, California--(Newsfile Corp. - January 15, 2019) - Next Green Wave Holdings Inc. (CSE: NGW) (OTCQB: NXGWF) ("Next Green Wave") and Intrexon Corporation (NASDAQ: XON) ("Intrexon") are pleased to announce they have entered into a strategic licensing agreement to utilize Intrexon's Botticelli™ next generation plant propagation platform to enable rapid production of Next Green Wave's proprietary cannabis cultivars ...

  • Markit8 days ago

    See what the IHS Markit Score report has to say about Intrexon Corp.

    # Intrexon Corp ### NASDAQ/NGS:XON View full report here! ## Summary * Bearish sentiment is high ## Bearish sentiment Short interest | Negative Short interest is high for XON with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting XON. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $5.45 billion over the last one-month into ETFs that hold XON are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • PR Newswire8 days ago

    Intrexon Partners with Next Green Wave to Advance Intrexon's Botticelli™ Next Generation Plant Propagation Platform into Development for Cannabis

    DAVIS, Calif. and COALINGA, Calif., Jan. 15, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON) ("Intrexon"), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, and Next Green Wave Holdings Inc. (NGW.CN) (NXGWF) ("Next Green Wave") are pleased to announce they have entered into a strategic licensing agreement to utilize Intrexon's Botticelli™ next generation plant propagation platform to enable rapid production of Next Green Wave's proprietary cannabis cultivars for the California market. The collaborative work conducted at Next Green Wave's facilities will also accelerate its vision of becoming a world-class nursery.

  • Next Green Wave Signs Licensing Agreement with Global Biotech Leader Intrexon
    Newsfile8 days ago

    Next Green Wave Signs Licensing Agreement with Global Biotech Leader Intrexon

    Companies to apply Intrexon's proprietary Botticelli(TM) platform toward rapid and sustainable cannabis plantlet production Coalinga, California and Davis, California--(Newsfile Corp. - January 15, 2019) -  Next Green Wave Holdings Inc. (CSE: NGW) (OTCQB: NXGWF) ("Next Green Wave") and Intrexon Corporation (NASDAQ: XON) ("Intrexon") are pleased to announce they have entered into a strategic licensing agreement to utilize Intrexon's Botticelli™ next generation plant propagation platform to enable rapid production of Next Green Wave's proprietary cannabis cultivars for ...

  • GlobeNewswire15 days ago

    Investing in a New Age of Cannabinoid Production for Cost Efficiency and Scalability

    Leading the way, NASDAQ’s first listed cannabis stock, Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) and Ginkgo Bioworks, the organism company, in early September announced a partnership to produce cultured cannabinoids.

  • PR Newswire21 days ago

    Intrexon Announces Presentations at Upcoming Investor Conferences

    GERMANTOWN, Md. , Jan. 2, 2019 /PRNewswire/ --   Intrexon Corporation  (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, ...

  • Precigen to Debut Portfolio at Investor Event during the 37th Annual J.P. Morgan Healthcare Conference
    PR Newswire23 days ago

    Precigen to Debut Portfolio at Investor Event during the 37th Annual J.P. Morgan Healthcare Conference

    Company to provide first-look at preclinical and clinical portfolio GERMANTOWN, Md. , Dec. 31, 2018 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) and a ...

  • Precigen to Host Conference Call to Provide Business Updates
    PR Newswirelast month

    Precigen to Host Conference Call to Provide Business Updates

    - Executive leadership to discuss recent announcements GERMANTOWN, Md. , Dec. 24, 2018 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON), and a biopharmaceutical ...

  • Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for First-in-Class PRGN-3006 UltraCAR-T™ Therapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndrome (MDS)
    PR Newswirelast month

    Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for First-in-Class PRGN-3006 UltraCAR-T™ Therapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndrome (MDS)

    - First CAR-T therapy to be administered within two days following non-viral gene transfer - First-in-class therapy for AML GERMANTOWN, Md. , Dec. 21, 2018 /PRNewswire/ -- Precigen, Inc., a wholly-owned ...

  • PR Newswirelast month

    Exemplar Genetics and Mayo Clinic Launch Joint Venture Focused on Development of Human Liver Cells to Advance Medical Research

    SIOUX CENTER, Iowa, Dec. 21, 2018 /PRNewswire/ -- Exemplar Genetics, a subsidiary of Intrexon Corporation (XON) and market leader in the development of genetically engineered miniswine as models of human disease, and Mayo Clinic have launched a joint venture focused on the development of a high quality source of human liver cells or hepatocytes (HHCs). The new company, Cytotheryx, headquartered in Rochester, Minnesota, will leverage the expertise and experience of Exemplar Genetics with the capabilities of Mayo Clinic's researchers to deliver this much-needed resource. Human hepatocytes are necessary for drug toxicology studies, hepatitis virus research and gene therapy testing.

  • GlobeNewswirelast month

    AquaBounty Technologies, Inc.: Issuance of USDA labeling rule

    AquaBounty Technologies, Inc. (AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (XON), is pleased to announce that the U.S. Department of Agriculture has released its disclosure standards for the labeling of products containing bioengineered components. The safety of these materials is assured by other regulatory processes, but the Bioengineered Food Disclosure Standard provides a national marketing standard to communicate the presence of these materials to consumers. Dr. Ronald Stotish, CEO, commented: “The issuance of these rules is a major step forward in providing a national standard for labeling foods and food materials in an objective and unbiased manner.

  • PR Newswirelast month

    Merck KGaA, Darmstadt, Germany, Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon

    DARMSTADT, Germany , December 20, 2018 /PRNewswire/ -- Not intended for UK-based media   Agreement enables Merck KGaA, Darmstadt, Germany , to maintain an investment in the rapidly advancing oncology field ...

  • PR Newswirelast month

    Intrexon and Merck KGaA, Darmstadt, Germany, Announce Agreement Realizing Precigen's Vision for Full Developmental Autonomy of its CAR-T Program

    - Merck KGaA, Darmstadt, Germany, to assign its Chimeric Antigen Receptor T-cell (CAR-T) rights to Intrexon - Intrexon to issue Merck KGaA, Darmstadt, Germany, $150 million in Intrexon stock and a $25 ...

  • PR Newswirelast month

    Intrexon and AquaBounty Receive Regulatory Exemption in Development of Gene Edited Tilapia for More Sustainable Production

    GERMANTOWN, Md. and MAYNARD, Mass., Dec. 18, 2018 /PRNewswire/ -- Intrexon Corporation (XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, and AquaBounty Technologies, Inc. (AQB), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon, announced that their jointly developed gene edited line of tilapia, FLT 01, is exempt from GM regulation according to Argentina's National Advisory Commission on Agricultural Biotechnology (CONABIA). This line of tilapia enables more sustainable production through improvements in fillet yield, growth and feed conversion efficiency, enabling the tilapia to grow to market weight in less time, while also consuming less feed than conventional varieties.

  • Do Options Traders Know Something About Intrexon (XON) Stock We Don't?
    Zackslast month

    Do Options Traders Know Something About Intrexon (XON) Stock We Don't?

    Investors need to pay close attention to Intrexon (XON) stock based on the movements in the options market lately.

  • Why Is Intrexon (XON) Down 31.5% Since Last Earnings Report?
    Zacks2 months ago

    Why Is Intrexon (XON) Down 31.5% Since Last Earnings Report?

    Intrexon (XON) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GlobeNewswire2 months ago

    New Research: Key Drivers of Growth for Intrexon, Graham, The Walt Disney, Toyota Motor, Atlas Air Worldwide, and SITO Mobile — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Oxitec Transitioning Friendly™ Self-limiting Mosquitoes to 2nd Generation Technology Platform, Paving Way to New Scalability, Performance and Cost Breakthroughs
    PR Newswire2 months ago

    Oxitec Transitioning Friendly™ Self-limiting Mosquitoes to 2nd Generation Technology Platform, Paving Way to New Scalability, Performance and Cost Breakthroughs

    OXFORD, England, Nov. 28, 2018 /PRNewswire/ -- Oxitec, Ltd, a UK-based biotechnology company that pioneered the use of biologically-engineered insects for control of disease-spreading Aedes aegypti mosquitoes and crop-destroying agricultural pests, announced today it will be transitioning from its 1st generation self-limiting Friendly™ Aedes aegypti mosquito (also known as "OX513A") to a new Friendly™ Aedes mosquito ("OX5034") that uses Oxitec's 2nd generation technology, allowing the company to focus on advancing its entire mosquito and crop pest portfolios using this next-generation platform. This transition comes after a decade of experience with Oxitec's 1st generation self-limiting Friendly™ Mosquito and after investments made to engineer new core features specifically designed to provide a range of additional benefits for end-users in vector control and agriculture.

  • GlobeNewswire2 months ago

    AquaBounty appoints Sylvia Wulf as Chief Executive Officer

    AquaBounty Technologies, Inc. (AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (XON), is pleased to announce the appointment of Sylvia Wulf as Chief Executive Officer and Executive Director effective on January 1, 2019. Sylvia Wulf joins AquaBounty from US Foods, Inc., one of the country’s leading food distributors, where she is currently a Senior Vice President and has been President of the Manufacturing Division since 2011.  Prior to US Foods, Ms. Wulf has held senior positions at Tyson Foods Inc, Sara Lee Corporation, and Bunge Corp., among others.  Additionally, she is currently on the Board of Directors and the Executive Committee of the National Fisheries Institute.  Her appointment has been planned to coincide with the Company’s developing emphasis on the commercialization of AquAdvantage Salmon, as the majority of the required regulatory hurdles have been passed.

  • ‘Not business as usual’: Rockville biotech’s new CEO wants to turn things around
    American City Business Journals2 months ago

    ‘Not business as usual’: Rockville biotech’s new CEO wants to turn things around

    The new chief executive had joined the company in January — after selling his last biotech company for several million dollars.

  • Intrexon (XON) Reports Narrower-Than-Expected Loss in Q3
    Zacks2 months ago

    Intrexon (XON) Reports Narrower-Than-Expected Loss in Q3

    Intrexon (XON) incurs narrower-than-expected loss, while revenues miss estimates in the third quarter of 2018.